^
Association details:
| Biomarker: | NOTCH3 underexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The immunosuppressive landscape of the NOTCH gene family in hepatocellular carcinoma (HCC).
Published date:
05/26/2022
Excerpt:
Exploratory subgroup analysis from the IMvigor210 trial on metastatic urothelial carcinoma patients on atezolizumab showed a significant difference in OS favoring low NOTCH3 expression (P = 0.003) and high APH1A expression (P = 0.049).
DOI:
10.1200/JCO.2022.40.16_suppl.e16139
Trial ID:
